Table 1.
Baseline characteristics of the subjects
| Donepezilgroup (N=72) |
Placebogroup (N=73) |
|
| Age, year, mean (SD) | 67.2(7.3) | 69.0(7.0) |
| Female sex, n (%) | 41(57) | 39(53) |
| PD duration, year, mean (SD) | 8.2(4.8) | 7.8(4.3) |
| Modified H-Y, n (%) | ||
| 2.5 | 36(50) | 38(52) |
| 3 | 25(35) | 29(40) |
| 4 | 11(15) | 6(8) |
| MMSE, mean (SD) | 27.8(1.9) | 27.7(2.1) |
| History of psychosis, n (%) | 25(35) | 25(34) |
| ESS, mean (SD) | 7.0(5.0) | 6.7(5.3) |
| UPDRS, mean (SD) | ||
| Part I | 0.8(1.0) | 0.6(0.9) |
| Part II ON | 6.6(5.2) | 6.2(4.8) |
| Part II OFF | 13.7(7.0) | 12.2(6.9) |
| Part III | 21.4(11.0) | 21.7(8.9) |
| Part IV | 3.2(2.5) | 2.6(2.3) |
| WMS, mean (SD) | ||
| Auditory | 49.8(18.8) | 45.0(19.2) |
| Visual | 48.8(10.8) | 46.1(12.0) |
| Attention | 57.1(11.6) | 56.3(8.5) |
| Delayed recall | 59.0(19.2) | 53.3(22.7) |
| FAB, mean (SD)* | 14.6(2.4) | 13.8(2.1) |
| LDED (mg/day) | 640.8(244.1) | 624.6(240.5) |
| Dopamine agonist user, n (%) | 48(66.7) | 52(71.2) |
| Amantadine user, n (%) | 18(25.0) | 15(20.5) |
| Apolipoprotein E4, n (%)† | 21(34.4) | 16(25.0) |
*n=70(donepezil), 73 (placebo), p=0.045.
†n=61(donepezil), 64 (placebo).
ESS, Epworth Sleepiness Scale; FAB, Frontal Assessment Battery; H-Y, Hoehn-Yahr; LDED, L-Dopa equivalent dose of dopaminergic replacement therapy; MMSE, Mini-Mental State Examination; PD, Parkinson’s disease; WMS, Wechsler Memory Scale.